An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

314

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Fragile X Syndrome
Interventions
DRUG

Zatolmilast/ BPN14770

25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)

Trial Locations (17)

10029

Icahn School of Medicine at Mount Sinai, New York

17579

Clinic for Special Children, Strasburg

19063

Suburban Research Associates, Media

21205

Kennedy Krieger Institute, Baltimore

29605

Greenwood Genetic Center, Greenville

30322

Emory University School of Medicine, Atlanta

33136

University of Miami, Miami

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60612

Rush University Medical Center, Chicago

66160

University of Kansas Medical Center, Kansas City

80045

Children's Hospital Colorado, Aurora

84113

University of Utah and Primary Children's Hospital, Salt Lake City

92604

Amnova Clinical Research, Irvine

92828

Thompson Autism & Neurodevelopment Center - CHOC, Orange

95817

MIND Institute UC Davis Medical Center, Sacramento

02115

Boston Children's Hospital, Boston

01655

U Mass, Worcester

Sponsors
All Listed Sponsors
lead

Tetra Discovery Partners

INDUSTRY

NCT05367960 - An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | Biotech Hunter | Biotech Hunter